Chart Events
Performance Outlook
| Previous Close | 34.90 |
| Open | 35.08 |
| Bid | 35.49 x 2200 |
| Ask | 35.53 x 1100 |
| Day's Range | 35.40 - 35.50 |
| 52 Week Range | 28.47 - 46.97 |
| Volume | |
| Avg. Volume | 3,652,398 |
| Market Cap | 72.822B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 13.31 |
| EPS (TTM) | 2.66 |
| Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
| Forward Dividend & Yield | 1.48 (4.24%) |
| Ex-Dividend Date | Feb 23, 2023 |
| 1y Target Est | 44.11 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GSK
Related Research
- GSK plcAnalyst Report: GSK PLCGSK plc, based in Brentford, UK, is a global healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceutical products. The company's leading products include treatments for asthma and COPD; products for HIV infection; and a range of vaccines. The company has active research and development programs in immuno-inflammation, neuroscience, metabolic pathways, ophthalmology, respiratory and infectious diseases, and biopharmaceuticals.RatingFair ValueEconomic Moatlast monthArgus Research
- Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
https://cdn.benzinga.com/files/images/story/2023/03/20/bird_flu-_image_by_jeyaratnam_caniceus_from_pixabay-.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Executives at GSK Plc (NYSE: GSK), Moderna Inc (NASDAQ: MRNA), and CSL Seqirus, owned by CSL Ltd (OTC: CSLLY), said they are developing or about to test sample human vaccines against bird flu as a precautionary measure against a future pandemic. Others, like Sanofi SA (NASDAQ: SNY), said they "stand ready" to begin production if needed, w
- InvestorPlace
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it’s much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing. The following three drug stocks certainly fit that criterion. One has a very promising treatment for cancer, which is a leading cause of death in both the U.S. an
- Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.
